STOCK TITAN

[SCHEDULE 13G/A] Kymera Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) is reported as having significant institutional ownership by Wellington Management and affiliated entities. The filing shows an aggregate beneficial ownership of 5,372,061 shares, representing approximately 7.66% of the outstanding common stock. The reporting parties state they have no sole voting or dispositive power and instead hold shared voting power of 4,872,818 shares and shared dispositive power of 5,372,061 shares. The securities are owned of record by clients of Wellington investment advisers and the filing is submitted on Schedule 13G, with a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.

Kymera Therapeutics, Inc. (KYMR) risulta avere una consistente partecipazione istituzionale detenuta da Wellington Management e soggetti affiliati. La comunicazione riporta un possesso beneficiario complessivo di 5.372.061 azioni, corrispondente a circa il 7,66% del capitale sociale ordinario in circolazione. Le parti segnalanti dichiarano di non avere alcun potere di voto o di disposizione in via esclusiva e di detenere invece un potere di voto condiviso su 4.872.818 azioni e un potere di disposizione condiviso su 5.372.061 azioni. I titoli sono registrati a nome di clienti dei gestori d'investimento di Wellington e la comunicazione è presentata secondo il Schedule 13G, con la certificazione che le azioni sono detenute nell'ambito della normale attività d'impresa e non con l'obiettivo di modificare o influenzare il controllo.

Kymera Therapeutics, Inc. (KYMR) figura con una significativa participación institucional atribuida a Wellington Management y entidades afiliadas. La presentación indica una participación beneficiaria agregada de 5.372.061 acciones, que representa aproximadamente el 7,66% del capital social ordinario en circulación. Las partes informantes declaran no tener poder exclusivo de voto ni de disposición y, en cambio, poseen un poder de voto compartido sobre 4.872.818 acciones y un poder de disposición compartido sobre 5.372.061 acciones. Los valores están registrados a nombre de clientes de los asesores de inversión de Wellington y la presentación se realiza en Schedule 13G, con la certificación de que las acciones se mantienen en el curso normal del negocio y no con la finalidad de cambiar o influir en el control.

Kymera Therapeutics, Inc. (KYMR)는 Wellington Management 및 계열사가 상당한 기관 보유를 보유한 것으로 보고되었습니다. 제출서류에는 총 수익적 보유 주식 5,372,061주가 기재되어 있으며 이는 유통 중인 보통주 약 7.66%에 해당합니다. 보고 당사자들은 단독 의결권 또는 처분권이 없다고 밝히고 대신 4,872,818주의 공동 의결권5,372,061주의 공동 처분권을 보유하고 있다고 명시했습니다. 해당 증권은 웰링턴 투자자문사의 고객 명의로 보유되어 있으며 제출은 Schedule 13G로 이루어졌고, 주식이 통상적인 영업 과정에서 보유되며 통제권을 변경하거나 영향을 미치기 위한 목적이 아니다라는 인증이 포함되어 있습니다.

Kymera Therapeutics, Inc. (KYMR) est signalée comme ayant une importante participation institutionnelle détenue par Wellington Management et des entités affiliées. La déclaration indique une participation bénéficiaire globale de 5 372 061 actions, représentant environ 7,66 % des actions ordinaires en circulation. Les parties déclarante précisent qu'elles n'ont ni pouvoir de vote ni pouvoir dispositif exclusif et détiennent plutôt un pouvoir de vote conjoint sur 4 872 818 actions et un pouvoir dispositif conjoint sur 5 372 061 actions. Les titres sont enregistrés au nom de clients des conseillers en investissement de Wellington et la déclaration est déposée au Schedule 13G, accompagnée de la certification que les actions sont détenues dans le cadre normal des activités et pas dans le but de changer ou d'influencer le contrôle.

Kymera Therapeutics, Inc. (KYMR) wird berichtet, dass Wellington Management und verbundene Stellen eine bedeutende institutionelle Beteiligung halten. Die Meldung weist eine zusammengefasste wirtschaftliche Eigentümerschaft von 5.372.061 Aktien aus, was etwa 7,66% des ausstehenden Stammkapitals entspricht. Die meldenden Parteien geben an, keine alleinige Stimm- oder Verfügungsgewalt zu haben, sondern stattdessen über gemeinsame Stimmrechte für 4.872.818 Aktien und gemeinsame Verfügungsrechte für 5.372.061 Aktien zu verfügen. Die Wertpapiere sind namensmäßig im Besitz von Kunden der Anlageberater von Wellington, und die Meldung wurde auf Schedule 13G eingereicht, mit der Bescheinigung, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit dem Zweck, die Kontrolle zu ändern oder zu beeinflussen.

Positive
  • Material institutional ownership: Wellington and affiliates report 5,372,061 shares (~7.66%) of Kymera common stock
  • Held for clients: Securities are owned of record by clients of Wellington investment advisers, indicating diversified, professional custody
  • Schedule 13G filing: The use of Schedule 13G and the included certification indicates the position is reported as passive and not to influence control
Negative
  • None.

Insights

TL;DR: Wellington and affiliates report a material passive stake of ~7.7% in Kymera, a meaningful institutional holding but not an activist position.

The Schedule 13G shows Wellington Management Group LLP and related entities collectively beneficially own 5,372,061 shares, about 7.66% of Kymera's common stock. The filing reports zero sole voting or dispositive power and material shared voting/dispositive figures, consistent with holdings managed on behalf of clients. Because the statement is filed on Schedule 13G with a certification that the shares are not held to influence control, this should be viewed as a significant institutional investment rather than an attempt to effect governance changes.

TL;DR: Disclosure reflects substantial client-directed holdings with shared control rights; no indication of pursuit of board or control actions.

The filing identifies multiple Wellington entities as reporting persons and clarifies that the securities are owned of record by clients of Wellington investment advisers. Reported metrics show 0 sole voting/dispositive power and reliance on shared authority, and the certification explicitly states the holdings are not intended to change or influence control. From a governance perspective, this positions Wellington as an influential institutional holder by size but not an activist or controlling shareholder per the filed disclosures.

Kymera Therapeutics, Inc. (KYMR) risulta avere una consistente partecipazione istituzionale detenuta da Wellington Management e soggetti affiliati. La comunicazione riporta un possesso beneficiario complessivo di 5.372.061 azioni, corrispondente a circa il 7,66% del capitale sociale ordinario in circolazione. Le parti segnalanti dichiarano di non avere alcun potere di voto o di disposizione in via esclusiva e di detenere invece un potere di voto condiviso su 4.872.818 azioni e un potere di disposizione condiviso su 5.372.061 azioni. I titoli sono registrati a nome di clienti dei gestori d'investimento di Wellington e la comunicazione è presentata secondo il Schedule 13G, con la certificazione che le azioni sono detenute nell'ambito della normale attività d'impresa e non con l'obiettivo di modificare o influenzare il controllo.

Kymera Therapeutics, Inc. (KYMR) figura con una significativa participación institucional atribuida a Wellington Management y entidades afiliadas. La presentación indica una participación beneficiaria agregada de 5.372.061 acciones, que representa aproximadamente el 7,66% del capital social ordinario en circulación. Las partes informantes declaran no tener poder exclusivo de voto ni de disposición y, en cambio, poseen un poder de voto compartido sobre 4.872.818 acciones y un poder de disposición compartido sobre 5.372.061 acciones. Los valores están registrados a nombre de clientes de los asesores de inversión de Wellington y la presentación se realiza en Schedule 13G, con la certificación de que las acciones se mantienen en el curso normal del negocio y no con la finalidad de cambiar o influir en el control.

Kymera Therapeutics, Inc. (KYMR)는 Wellington Management 및 계열사가 상당한 기관 보유를 보유한 것으로 보고되었습니다. 제출서류에는 총 수익적 보유 주식 5,372,061주가 기재되어 있으며 이는 유통 중인 보통주 약 7.66%에 해당합니다. 보고 당사자들은 단독 의결권 또는 처분권이 없다고 밝히고 대신 4,872,818주의 공동 의결권5,372,061주의 공동 처분권을 보유하고 있다고 명시했습니다. 해당 증권은 웰링턴 투자자문사의 고객 명의로 보유되어 있으며 제출은 Schedule 13G로 이루어졌고, 주식이 통상적인 영업 과정에서 보유되며 통제권을 변경하거나 영향을 미치기 위한 목적이 아니다라는 인증이 포함되어 있습니다.

Kymera Therapeutics, Inc. (KYMR) est signalée comme ayant une importante participation institutionnelle détenue par Wellington Management et des entités affiliées. La déclaration indique une participation bénéficiaire globale de 5 372 061 actions, représentant environ 7,66 % des actions ordinaires en circulation. Les parties déclarante précisent qu'elles n'ont ni pouvoir de vote ni pouvoir dispositif exclusif et détiennent plutôt un pouvoir de vote conjoint sur 4 872 818 actions et un pouvoir dispositif conjoint sur 5 372 061 actions. Les titres sont enregistrés au nom de clients des conseillers en investissement de Wellington et la déclaration est déposée au Schedule 13G, accompagnée de la certification que les actions sont détenues dans le cadre normal des activités et pas dans le but de changer ou d'influencer le contrôle.

Kymera Therapeutics, Inc. (KYMR) wird berichtet, dass Wellington Management und verbundene Stellen eine bedeutende institutionelle Beteiligung halten. Die Meldung weist eine zusammengefasste wirtschaftliche Eigentümerschaft von 5.372.061 Aktien aus, was etwa 7,66% des ausstehenden Stammkapitals entspricht. Die meldenden Parteien geben an, keine alleinige Stimm- oder Verfügungsgewalt zu haben, sondern stattdessen über gemeinsame Stimmrechte für 4.872.818 Aktien und gemeinsame Verfügungsrechte für 5.372.061 Aktien zu verfügen. Die Wertpapiere sind namensmäßig im Besitz von Kunden der Anlageberater von Wellington, und die Meldung wurde auf Schedule 13G eingereicht, mit der Bescheinigung, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht mit dem Zweck, die Kontrolle zu ändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025

FAQ

How many KYMR shares does Wellington report owning?

Wellington and affiliated filers report beneficial ownership of 5,372,061 shares of Kymera common stock.

What percentage of KYMR does Wellington own?

The filing reports ownership of approximately 7.66% of Kymera's outstanding common stock.

Does Wellington have sole voting or dispositive power over these KYMR shares?

No. The reporting entities state 0 sole voting power and 0 sole dispositive power, with 4,872,818 shared voting and 5,372,061 shared dispositive powers reported.

Are the shares held to influence control of Kymera (KYMR)?

According to the certification in the filing, the securities are held in the ordinary course of business and were not acquired and are not held to change or influence control of the issuer.

Which Wellington entities filed the Schedule 13G for KYMR?

The filing lists: Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP as reporting persons.
Kymera Therapeutics, Inc.

NASDAQ:KYMR

KYMR Rankings

KYMR Latest News

KYMR Latest SEC Filings

KYMR Stock Data

2.91B
68.12M
2.5%
105.65%
10.79%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN